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Abstract 
Objective 
To quantify photophobia in visual snow syndrome (VSS), a debilitating migraine-
associated visual disturbance manifesting with continuous “TV snow-like“ flickering 
dots in the entire visual field and additional visual symptoms, such as photophobia. 
 
Methods 
Photophobia was compared between 19 patients with VSS and 19 controls matched for 
age, sex, migraine and aura using the Leiden Visual Sensitivity Scale (L-VISS). 
 
Results 
Patients with VSS had an increased L-VISS-score compared to matched controls 
[22.2±5.9 vs. 4.4±4.8; ANOVA, factors VSS and comorbid migraine: main effect for 
VSS (F=100.70; p<0.001), but not for migraine (F<0.01; p=1.00) or the interaction 
(F=1.93; p=0.16)]. An L-VISS-score of 14 identified VSS with a sensitivity and 
specificity of 95% (Receiver Operating Characteristic analysis, 0.986±0.014, p≤0.001).  
 
Conclusion 
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Patients with VSS suffer continuously from photophobia at a level similar to chronic 
migraineurs during attacks. Although migraine and VSS share dysfunctional visual 
processing, patients with VSS might be more severely affected. 
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Introduction 
Patients with visual snow syndrome (VSS, ICHD-III A1.4.6) suffer from continuous 
TV-static-like tiny flickering dots in the entire visual field, i.e. visual snow (VS) and 
additional visual symptoms, such as palinopsia and photophobia1, 2. The syndrome is 
highly disabling due to the continuous presence and the lack of treatment options3. Its 
pathophysiology is unclear with some overlap with migraine and aura2. The clinical 
picture of VS, palinopsia, enhanced entoptic phenomena and photophobia2, 
hypermetabolism of the lingual gyrus4, and increased latency of N145 in visual evoked 
potentials5 suggest impairment of higher order visual cortex function, although there is 
also evidence of a more proximal dysfunction 6. 
 
Photophobia, i.e. “normal” light causing discomfort in the eye or head7, is a hallmark 
not only of VSS2, but also of migraine attacks1, where it can be attributed to a 
dysfunction of the extra striate visual cortex8, or the thalamus9, or both. Studying 
photophobia in VSS might improve our understanding of the common basis of VSS and 
migraine with possible implications for therapy in the future. Here, we used the 
validated Leiden Visual Sensitivity Scale (L-VISS) to investigate whether the extent of 
photophobia differs between VSS patients and controls. 
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Patients and methods 
The study was conducted in accordance with the Declaration of Helsinki and approved 
by the ethics committee of the Ludwig Maximilians University Munich (227-15). All 
patients gave written informed consent. 
 
Subject recruitment 
Subjects were recruited from 2015 to 2017 using advertisements in social media with 
support from the self-help group “Eye on Vision Foundation” (www.eyeonvision.org). 
After being contacted by patients, we explained the study over the phone and assessed 
the inclusion criteria (age ≥18 years and presence of VS syndrome, subtype black and 
white)2 and the exclusion criterion (history of illicit drug use). Eligible patients were 
invited to a visit at our out-patient clinic, where they all had a neurological exam and 
standard visual evoked potentials (VEPs) to exclude anterior visual pathway pathology. 
Controls were recruited from the outpatient headache clinic or among co-workers from 
our hospital. They were matched for age, sex, migraine and aura1, and did not have VS. 
We did not specifically address other visual symptoms, and did not perform VEPs in 
controls. In patients with comorbid migraine, frequency of headache was approximated 
using Migraine Disability Assessment part A (MIDAS-A)10, and severity was assessed 
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using MIDAS or Headache Impact Test-6 (HIT-6)11, or both. Headache diaries were not 
used.  
 
Measurement of visual sensitivity 
Visual sensitivity was measured using Leiden Visual Sensitivity Scale (L-VISS), a 9 
items 5-point Likert-type response scale validated in migraine patients12, 13. Subjects 
with comorbid migraine had been free of headache for at least 48 hours before filling in 
the questionnaire. No subject reported having a migraine attack within the 48 hours 
following study participation. 
 
Statistical analysis 
Statistical analysis was done using IBM SPSS Statistics Version 25 (IBM Corp. 
Released 2017. Armonk, NY). Statistical significance was assumed at p≤0.05 (two-
tailed). Normal distribution was assessed using Kolmogorov-Smirnov-Test. Group 
characteristics were compared using chi-square test, t-test, and Mann-Whitney U test as 
appropriate. Group differences in L-VISS-score were assessed with ANOVA, using 
VSS and comorbid migraine as factors. For the comparison of pre-specified subgroups 
stratified for migraine and aura comorbidity, t-test was used. Values are expressed as 
  Eren et a. 8 
 
mean±standard deviation (SD), or median (25th; 75th percentile). Cut off values to 
differentiate between VSS and controls were calculated using Receiver Operating 
Characteristic (ROC) curve analysis. 
 
Data Availability Statement 
Anonymized data will be shared by request from any qualified investigator.  
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Results 
Subjects 
Nineteen patients with VSS (7 females; 13 with comorbid migraine, 6 of them with 
typical visual migraine aura; one patient had visual aura without headache) were 
compared to 19 matched control subjects (7 females; 13 with comorbid migraine, 9 of 
them with typical visual migraine aura). Migraine was episodic in all subjects except for 
one VSS patient and one control subject, who had chronic migraine. Group 
characteristics including severity of comorbid migraine did not differ (Table). Patients 
with VSS were on the following medication, started for VSS treatment, not for migraine 
prophylaxis: lamotrigine (n=1), antihypertensives (n=2), and antidepressants (n=5). 
None had any effect on VSS. Control subjects did not use any migraine prophylactics. 
In all VSS patients, neurological exam, ophthalmological exam (performed before 
presentation to our center), standard structural brain MRI, and routine visual evoked 
potentials (N75-P100 amplitude and P100 latency) were within normal limits. Details of 
visual evoked potentials in a group of VSS patients overlapping with our population 
have been reported recently5. 
 
Visual sensitivity 
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Patients with VSS had an increased L-VISS-score compared to age-, sex-, migraine- 
and aura-matched controls (22.2±5.9 vs. 4.4±4.8, Figure a). In ANOVA, there was a 
main effect of VSS (F=100.70; p<0.001), but not of comorbid migraine (F<0.01; 
p=1.00), and no interaction between the two (F=1.93; p=0.16). After stratification for 
the presence of migraine and aura, all VSS subgroups had increased L-VISS-scores 
compared to the respective control group: no comorbid migraine (VSS vs. controls: 
24.3±7.6 vs. 2.2±3.7; T=6.4; df=10; p<0.001), comorbid migraine without aura 
(22.3±4.1 vs. 4.0±2.7; T=7.7; df=8; p<0.001), comorbid migraine with aura (20.1±5.8 
vs. 6.1±5.9; T=4.8; df=14; p<0.001; Figure b). 
Receiver Operating Characteristic (ROC) analysis between VSS and controls showed an 
area under the ROC curve of 0.986±0.014 (p≤0.001). An L-VISS-score of 14 points 
differentiated best between both groups with a sensitivity and specificity of 95% each.  
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Discussion 
Patients with VSS have increased visual sensitivity measured with the Leiden Visual 
Sensitivity Scale (L-VISS) independent of comorbid migraine and aura. The L-VISS is 
a self-report instrument developed to quantify visual sensitivity to light (photophobia) 
on an almost continuous linear scale. It has excellent internal consistency, test-retest 
reproducibility, and correlates well with established psychophysical tests (pattern glare 
and light discomfort test) making it an important method for quantifying visual 
sensitivity12. 
While the L-VISS-score in our control group (4.4±4.8) was in the range of healthy 
controls (3.6±2.8) and interictal migraineurs (11.3±5.4) from the Perenboom study12, 
patients with VSS (22.2±5.9) almost reached values found in patients with chronic 
migraine with aura during the attacks (25.8±7.9)12. Since all subjects with comorbid 
migraine were studied in the interictal phase, a bias due to assessment of VSS patients 
during migraine attacks is highly unlikely. Further, the group differences were not 
driven by migraine severity since both groups were similarly affected by migraine 
according to HIT-6 and MIDAS scores. The extent of sensitivity to light in patients with 
VSS reaches a level similar to that of migraineurs during their headache attacks, when 
patients typically withdraw from daily routine into dark places. The relevant difference 
is that photophobia is continuous in VSS and restricted to attacks in migraine. This 
study quantifying one of the major symptoms of VSS is relevant for daily clinical 
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practice. It relates the suffering of patients with VSS to the suffering of migraine and 
emphasises the impact of VSS on visual function. 
A previous study demonstrated that comorbid migraine worsens VSS by increasing the 
risk of having additional visual symptoms, such as palinopsia or photophobia4. This 
might suggest that VSS patients with comorbid migraine might also have higher levels 
of photophobia than VSS patients without migraine. This hypothesis was not confirmed 
by our data showing that the visual sensitivity measured in L-VISS is excessive in VSS 
independent from comorbid migraine or aura. Instead, comorbid migraine might 
increase the risk of having photophobia in VSS4, but when present, the suffering from 
visual sensitivity is severe, but uncoupled from migraine. This is important for our 
understanding of the interaction of migraine and VSS. Migraine might increase the risk 
of developing VSS with additional symptoms, but VSS may not follow a migrainous 
modulation. This is supported by VSS symptoms being constant without fluctuations 
during migraine attacks2, and by the tenacious resistance to migraine pharmacological 
therapy3. 
 
The mechanism of VSS remains enigmatic. In migraine, photophobia has been 
attributed to thalamic or thalamocortical dysfunction9 and to hyperactivity or 
hyperresponsiveness of the visual cortex8. In migraine, such hyperresponsiveness can be 
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reduced by the migraine prophylactics topiramate14 and beta-blockers15 or by the 
antidepressant fluoxetine16. In our study, only patients with VSS were on migraine 
prophylaxis for the treatment of VSS. Assuming a correlation between 
hyperresponsiveness and L-VISS score12, this would result in a reduction of L-VISS. In 
contrast, L-VISS score was increased in VSS suggesting that a bias from treatment with 
migraine prophylactics is unlikely. For VSS, hypermetabolism of the visual association 
cortex4, alterations of visual evoked potentials5, and a potential thalamocortical 
dysrhythmia17 suggest involvement of mechanisms similar to migraine. Understanding 
how these mechanisms are differently conducted in both conditions, and how the 
primary visual cortex is involved6, might be necessary to generate hypotheses on how to 
treat VSS. 
The limitations of this study are the small sample size in the subgroups stratified for 
comorbid migraine and the approximation of migraine burden by using scales instead of 
headache diaries. The prevalence of VSS is unknown and so is the sex distribution. 
Patients were recruited based on their interest in participating without aiming at a male-
female ratio typical for migraine. Therefore, it remains to be determined if there is a 
bias resulting from the male predominance in our study. Although excessive visual 
sensitivity in VSS is independent from comorbid migraine, the direct effect of comorbid 
migraine or aura on visual sensitivity in VSS could not be assessed and would require 
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future studies using larger numbers of subjects, ideally without migraine prophylactic 
therapy. 
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Conclusion 
Increased sensitivity to light in patients with visual snow syndrome is independent from 
comorbid migraine or aura. The suffering from light sensitivity is continuous in VSS 
and in the range of photophobia during migraine attacks. The uncoupling of light 
sensitivity from migraine might explain the failure of migraine preventives in VSS. 
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Clinical implications 
- This study quantifies photophobia in patients with visual snow syndrome. 
- Photophobia is continuous at a level comparable to migraineurs during attacks 
emphasizing the disability caused by visual snow syndrome. 
- Excessive photophobia in visual snow syndrome is independent from comorbid 
migraine or migraine aura. 
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Figure 
Enhanced visual sensitivity in visual snow syndrome (VSS) compared to matched 
controls (C) 
Patients with visual snow syndrome have increased visual sensitivity measured with 
Leiden Visual Sensitivity Scale (L-VISS) when compared to controls matched for age, 
sex, migraine and aura (in a, ANOVA with factors VSS and comorbid migraine). In 
subgroup analysis (in b, t test) stratified for no comorbid migraine (M-), comorbid 
migraine without (MO), and migraine with aura (MA), the difference persists. 
Individual values are shown as dots (VSS) or circles (controls). Mean values are shown 
as horizontal bars (* p<0.001). 
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Table 
Characteristics of study population including additional visual symptoms in patients 
with VSS (not present in control population). 
